Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences sBC expense — Research and development ($M) ($M)
Form 10-Q / 10-K Note 13 Stock-Based Compensation
Latest, FY2025
433
Period ended Dec 31, 2025
Change on a year earlier
-5.5%
458 in FY2024
History
12 years
Since FY2014
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SBC expense — Research and development ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 433 | -5.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 458 | +21.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 377 | +32.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 285 | -0.7% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 287 | -37.9% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 462 | +59.9% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 289 | -23.7% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 379 | +63.4% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 232 | +31.8% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 176 | +1.7% | Form 10-K (filed 2019-02-26) ↗ |
| FY2015 | Dec 31, 2015 | 173 | +13.8% | Form 10-K (filed 2018-02-27) ↗ |
| FY2014 | Dec 31, 2014 | 152 | – | Form 10-K (filed 2017-02-27) ↗ |
Cite this data
StockData. (2026). Gilead Sciences SBC expense — Research and development ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/sbc_rd
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.